Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced
April 21, 2008
Genzyme Pompe Program Update—April 2008
We would like to take this opportunity to provide an important update related to Myozyme (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme.) manufacturing in the
January 15, 2008
January 2008 US Myozyme Supply Update
In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in
December 13, 2007
Genzyme Study of Myozyme® for Late-Onset Pompe Patients
CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme® (alglucosidase alfa)
June 27, 2007
MTAP Fact Sheet June 2007
MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a
June 27, 2007
Genzyme Pompe Program Update—June 2007
Genzyme would like to take this opportunity to provide a brief update to the Pompe patient community regarding the US
May 2, 2007
MTAP Fact Sheet May 2007
MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a
April 24, 2007
Genzyme Pompe Program Update—April 2007
As many of you are aware, a standard part of the biologics drug development process is to incrementally scale-up manufacturing
November 24, 2006
2006 Conference
2006 AMDA/IPA Conference Report By Allan Muir With contributions from George Fox and Jared Salbato Friday—November 17, 2006 Texas Hoe